Emgality works differently than many other preventive medications1-3

Emgality is a humanized monoclonal antibody specficially developed to bind to CGRP1

Binding of CGRP molecule

There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1



Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

CGRP is thought to play a key role in migraine4

Elevated levels of CGRP can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP.4

CGRP molecule binding to receptor
  • CGRP, released from the trigeminal ganglia, is elevated during migraine attacks4
  • Perivascular release of CGRP has been shown to induce vasodilation and plasma protein leakage from tissues4
  • An infusion of CGRP can induce migraine attacks in susceptible individuals, and CGRP is involved in the transmission of pain5,6

CGRP=calcitonin gene-related peptide.


  1. Emgality. Prescribing information. Lilly USA, LLC.
  2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552.
  3. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281-291.
  4. Durham PL. CGRP-receptor antagonists—A fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073-1075.
  5. Lassen L, Haderslev P, Jacobsen V, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54-61.
  6. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Research. 1987;403(2):350-354.


Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.



Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache